GAMMA Investing LLC Purchases 39,991 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

GAMMA Investing LLC boosted its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 4,682.8% in the 1st quarter, HoldingsChannel.com reports. The firm owned 40,845 shares of the biotechnology company’s stock after buying an additional 39,991 shares during the period. GAMMA Investing LLC’s holdings in Sarepta Therapeutics were worth $2,607,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its stake in Sarepta Therapeutics by 2.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after purchasing an additional 12,000 shares during the period. Proficio Capital Partners LLC bought a new stake in Sarepta Therapeutics in the 4th quarter valued at $3,829,000. Allspring Global Investments Holdings LLC boosted its stake in Sarepta Therapeutics by 16,717.7% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock valued at $10,602,000 after purchasing an additional 84,926 shares during the period. Van ECK Associates Corp boosted its stake in Sarepta Therapeutics by 24.4% in the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock valued at $10,315,000 after purchasing an additional 16,658 shares during the period. Finally, PNC Financial Services Group Inc. boosted its stake in Sarepta Therapeutics by 5.3% in the 4th quarter. PNC Financial Services Group Inc. now owns 2,891 shares of the biotechnology company’s stock valued at $352,000 after purchasing an additional 145 shares during the period. 86.68% of the stock is currently owned by institutional investors.

Sarepta Therapeutics Price Performance

Sarepta Therapeutics stock opened at $37.31 on Friday. Sarepta Therapeutics, Inc. has a 52 week low of $34.10 and a 52 week high of $173.25. The stock has a fifty day moving average of $46.51 and a 200-day moving average of $87.40. The company has a debt-to-equity ratio of 0.93, a quick ratio of 3.03 and a current ratio of 3.84. The stock has a market capitalization of $3.67 billion, a P/E ratio of 29.85 and a beta of 0.61.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). Sarepta Therapeutics had a return on equity of 11.00% and a net margin of 7.43%. The firm had revenue of $744.86 million during the quarter, compared to analyst estimates of $685.75 million. During the same period in the previous year, the company earned $0.73 EPS. Sarepta Therapeutics’s revenue for the quarter was up 80.2% on a year-over-year basis. On average, sell-side analysts expect that Sarepta Therapeutics, Inc. will post 2.67 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Guggenheim dropped their price objective on Sarepta Therapeutics from $112.00 to $98.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. The Goldman Sachs Group dropped their price objective on Sarepta Therapeutics from $178.00 to $100.00 and set a “buy” rating for the company in a report on Wednesday, May 7th. HC Wainwright reaffirmed a “neutral” rating and issued a $40.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, May 22nd. Morgan Stanley dropped their price objective on Sarepta Therapeutics from $182.00 to $113.00 and set an “overweight” rating for the company in a report on Wednesday, May 7th. Finally, Wells Fargo & Company dropped their price objective on Sarepta Therapeutics from $115.00 to $100.00 and set an “overweight” rating for the company in a report on Thursday, May 8th. Five analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $122.61.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.